Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.

about

Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.Molecular heterogeneity in hepatocellular carcinoma Gd-EOB-DTPA DCE-MRI biomarkers in a rabbit model of liver fibrosis

P2860

Q41921861-DFEBEC1A-F766-45EA-A1CB-63B911228870 Q57300487-EDD7B13F-B7D7-4E4B-B817-BC4D25EBECCA Q57493366-2A3376CD-6E1D-4875-AE05-2DF65E702663

P2860

Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.

Item

http://www.wikidata.org/entity/Q38702281

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Cost effectiveness of regorafe ...... nced hepatocellular carcinoma.

@en

type

Item

label

Cost effectiveness of regorafe ...... nced hepatocellular carcinoma.

@en

prefLabel

Cost effectiveness of regorafe ...... nced hepatocellular carcinoma.

@en

P1476

Cost effectiveness of regorafe ...... anced hepatocellular carcinoma

@en

P2093

Amit G Singal

http://www.w3.org/2001/XMLSchema#string

David W Hutton

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hepatocellular carcinoma: An update

Sorafenib in advanced hepatocellular carcinoma

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.

Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Earlier presentation and application of curative treatments in hepatocellular carcinoma.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.

P304

3725-3731

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.30863

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Neehar D Parikh

P577

2017-06-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28662266

http://www.w3.org/2001/XMLSchema#string

Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.

about

P2860

P2860

Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698